Cipla Ltd.

BSE: 500087 | NSE: CIPLA
Mid Cap | Pharmaceuticals & Drugs
1458.45
2.20 (0.15%)
< Home < Back

Cipla gets tentative nod from US FDA for its HIV treatment tablets

Date: 18-10-2012

Cipla has received a tentative approval from United States Food and Drug Administration (US FDA) for its HIV treatment tablets, which have a combination of lamivudine, nevirapine and zidovudine drugs.

The company sells the combination drug under the brand name ‘Duovir N’ outside the United States.

Cipla focuses on development of new formulations and has a wide range of pharmaceutical products. It offers prescription drugs, bulk drugs, animal products and pesticides. It also offers a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products.